drugset / Trial / NCT02721069

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

NCT02721069

Phase 3 Completed 175 enrolled Neurelis, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1

Timeline

Start
2016-04-11
Primary completion
2020-06-17
Completion
2020-07-23

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Diazepam Small molecule 5 mg Intranasal
Subject Diazepam Small molecule 10 mg Intranasal
Subject Diazepam Small molecule 15 mg Intranasal
Subject Diazepam Small molecule 20 mg Intranasal

Indications